Crestwood Advisors Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.63M | Buy |
20,797
+937
| +5% | +$123K | 0.04% | 214 |
|
|
2026
Q1 | $2.77M | Buy |
19,860
+1,617
| +9% | +$226K | 0.05% | 198 |
|
|
2025
Q4 | $2.24M | Buy |
18,243
+903
| +5% | +$110K | 0.04% | 209 |
|
|
2025
Q3 | $1.92M | Buy |
17,340
+1,428
| +9% | +$162K | 0.03% | 216 |
|
|
2025
Q2 | $1.76M | Buy |
15,912
+955
| +6% | +$102K | 0.03% | 222 |
|
|
2025
Q1 | $1.68M | Buy |
14,957
+460
| +3% | +$47.5K | 0.03% | 218 |
|
|
2024
Q4 | $1.34M | Buy |
14,497
+2,321
| +19% | +$209K | 0.03% | 219 |
|
|
2024
Q3 | $1.02M | Buy |
12,176
+1,116
| +10% | +$85.2K | 0.02% | 232 |
|
|
2024
Q2 | $759K | Sell |
11,060
-5,053
| -31% | -$337K | 0.02% | 244 |
|
|
2024
Q1 | $1.18M | Buy |
16,113
+60
| +0.4% | +$4.61K | 0.03% | 205 |
|
|
2023
Q4 | $1.3M | Sell |
16,053
-339
| -2% | -$26.4K | 0.03% | 191 |
|
|
2023
Q3 | $1.23M | Buy |
+16,392
| New | +$1.26M | 0.03% | 179 |
|
|
2021
Q1 | – | Sell |
-7,822
| Closed | -$456K | – | 267 |
|
|
2020
Q4 | $456K | Sell |
7,822
-964
| -11% | -$58.2K | 0.02% | 196 |
|
|
2020
Q3 | $555K | Sell |
8,786
-2,611
| -23% | -$181K | 0.02% | 162 |
|
|
2020
Q2 | $877K | Buy |
11,397
+129
| +1% | +$9.89K | 0.04% | 129 |
|
|
2020
Q1 | $842K | Sell |
11,268
-1,364
| -11% | -$94.3K | 0.04% | 126 |
|
|
2019
Q4 | $821K | Sell |
12,632
-1,271
| -9% | -$82.8K | 0.03% | 143 |
|
|
2019
Q3 | $881K | Sell |
13,903
-1,488
| -10% | -$97.3K | 0.04% | 137 |
|
|
2019
Q2 | $1.04M | Buy |
+15,391
| New | +$1.01M | 0.05% | 130 |
|
|
2017
Q4 | – | Sell |
-2,735
| Closed | -$222K | – | 197 |
|
|
2017
Q3 | $222K | Buy |
2,735
+5
| +0.2% | +$382 | 0.02% | 141 |
|
|
2017
Q2 | $207K | Buy |
2,730
+279
| +11% | +$18.6K | 0.02% | 139 |
|
|
2017
Q1 | $168K | Sell |
2,451
-1,778
| -42% | -$125K | 0.01% | 150 |
|
|
2016
Q4 | $303K | Buy |
4,229
+208
| +5% | +$15.5K | 0.03% | 120 |
|
|
2016
Q3 | $318K | Sell |
4,021
-157
| -4% | -$12.8K | 0.04% | 98 |
|
|
2016
Q2 | $349K | Sell |
4,178
-11,053
| -73% | -$981K | 0.04% | 98 |
|
|
2016
Q1 | $1.4M | Sell |
15,231
-1,743
| -10% | -$157K | 0.17% | 59 |
|
|
2015
Q4 | $1.72M | Buy |
16,974
+2,906
| +21% | +$302K | 0.21% | 57 |
|
|
2015
Q3 | $1.38M | Sell |
14,068
-2,193
| -13% | -$244K | 0.18% | 55 |
|
|
2015
Q2 | $1.9M | Buy |
16,261
+10,059
| +162% | +$1.1M | 0.25% | 49 |
|
|
2015
Q1 | $609K | Buy |
6,202
+3,291
| +113% | +$334K | 0.09% | 73 |
|
|
2014
Q4 | $274K | Buy |
+2,911
| New | +$301K | 0.04% | 107 |
|
Other funds holding GILD
Crestwood Advisors Group's GILD Position: Q2 2026 in Review
Crestwood Advisors Group increased its Gilead Sciences (GILD) stake by 4.7% in Q2 2026, buying an estimated $123K and bringing the position to 20,797 shares worth $2.63M. The position accounts for 0.04% of the portfolio, ranked #214.
Crestwood Advisors Group first reported a position in GILD in Q4 2014 and has held it in 31 quarters since. The position peaked at $2.77M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Crestwood Advisors Group held 20,797 shares of Gilead Sciences worth $2.63M as of Q2 2026.
- Crestwood Advisors Group bought 937 Gilead Sciences shares in Q2 2026, an estimated $123K.
- Gilead Sciences made up 0.04% of Crestwood Advisors Group's portfolio in Q2 2026, its #214 holding.
- Crestwood Advisors Group first reported a position in Gilead Sciences in Q4 2014 and has held it in 31 quarters since.
- Crestwood Advisors Group's Gilead Sciences position peaked at $2.77M in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Crestwood Advisors Group's 13F filing for Q2 2026, filed 3 Aug 2026.